VEGFB and metabolic dysfunction-associated steatotic liver disease: Emerging evidence suggests VEGF-C as a therapeutic target for NAFLD, with flavonoid-based interventions showing potential in modulating VEGF-C activity.590 The interplay between VEGF-A, VEGF-B, and VEGF-C contributes to hepatic lipid accumulation, fibrosis, and carcinogenesis, highlighting VEGF signaling as a critical target for therapeutic strategies in NAFLD.